Myelodysplastic Syndromes
December 2022 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Myelodysplastic Syndromes abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Myelodysplastic Syndromes. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Myelodysplastic Syndromes. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Myelodysplastic Syndromes every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:TKIs combined with chemotherapy followed by allo-HSCT in Philadelphia chromosome-positive myelodysplastic syndrome: A case report and literature review.
Authors:Qi S, Wang F, Liu Y, Zhao J, Wang Y, Huang S, Yang W, Li Y, Shen Y, Zhang C, Zhao J, Yang X, Gao R, Chen Y, Zhao P, Zhang F, Huang Y, Zhao M, Wang P, Zhang Y, Dou H, Wang J, Li Y
Institution:Guizhou Medical University, Guiyang, China.
Journal:Medicine (Baltimore). 2022 Nov 18;101(46):e31874. doi: 10.1097/MD.0000000000031874.

2:Myelodysplastic syndromes.
Authors:Li H, Hu F, Gale RP, Sekeres MA, Liang Y
Institution:Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China. liangyang@sysucc.org.cn.
Journal:Nat Rev Dis Primers. 2022 Nov 17;8(1):74. doi: 10.1038/s41572-022-00402-5.

3:Myelodysplastic neoplasms: An overview on diagnosis, risk-stratification, molecular pathogenesis, and treatment.
Authors:Marques FK, Sabino AP
Institution:Research and Development Department, Hermes Pardini Institute, 2448 Nacoes Avenue, Vespasiano, Minas Gerais 33200-000, Brazil; Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, 6627 President Antonio Carlos Avenue, Belo Horizonte, Minas Gerais 31270-901, Brazil. Electronic address: fabiana.marques@grupopardini.com.br.; Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, 6627 President Antonio Carlos Avenue, Belo Horizonte, Minas Gerais 31270-901, Brazil. Electronic address: adriansabin01@gmail.com.
Journal:Biomed Pharmacother. 2022 Dec;156:113905. doi: 10.1016/j.biopha.2022.113905. Epub 2022 Oct 25.

4:Decreased FOXO1 Expression Is Correlated with Poor Prognosis in Myelodysplastic Syndromes.
Authors:Zhang Z, Huang N, Xv F, Zhao S, Guo J, Zhao Y, Chang C
Institution:Department of Hematology, Shanghai JiaoTong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
Journal:Curr Oncol. 2022 Sep 25;29(10):6933-6946. doi: 10.3390/curroncol29100545.

5:Real world data on the prognostic significance of monocytopenia in myelodysplastic syndrome.
Authors:Diamantopoulos PT, Charakopoulos E, Symeonidis A, Kotsianidis I, Viniou NA, Pappa V, Pontikoglou C, Tsokanas D, Drakos G, Kourakli A, Solomou E, Hatzimichael E, Pouli A, Kotsopoulou M, Asmanis E, Dimou M, Panayiotidis P, Papageorgiou S, Vassilopoulos G, Anagnostopoulos A, Vassilakopoulos T, Papadaki H, Galanopoulos A
Institution:Hematology Unit, First Department of Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, 'Laikon' General Hospital, 11527, Athens, Greece. pandiamantopoulos@gmail.com.; Department of Clinical Hematology, 'G. Gennimatas' District General Hospital, Athens, Greece.
Journal:Sci Rep. 2022 Oct 26;12(1):17914. doi: 10.1038/s41598-022-21933-7.

6:TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.
Authors:Daver NG, Maiti A, Kadia TM, Vyas P, Majeti R, Wei AH, Garcia-Manero G, Craddock C, Sallman DA, Kantarjian HM
Institution:Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Journal:Cancer Discov. 2022 Nov 2;12(11):2516-2529. doi: 10.1158/2159-8290.CD-22-0332.

7:Five-day versus 7-day treatment regimen with azacitidine in lower risk myelodysplastic syndrome: A phase 2, multicenter, randomized trial.
Authors:Park S, Park SY, Lee JH, Choi EJ, Lee KH, Yoon SS, Hong J, Shin DY, Kim YJ
Institution:Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, Catholic University of Korea, Seoul, Korea.
Journal:Cancer. 2022 Dec 1;128(23):4095-4108. doi: 10.1002/cncr.34492. Epub 2022 Oct 8.

8:Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT.
Authors:Raj K, Eikema DJ, Sheth V, Koster L, de Wreede LC, Blaise D, Di Grazia C, Koc Y, Potter V, Chevallier P, Lopez-Corral L, Wu D, Mielke S, Maertens J, Meijer E, Huynh A, Passweg J, Luft T, Pérez-Simón JA, Ciceri F, Piekarska A, Hayri Ozsan G, Kröger N, Robin M, Yakoub-Agha I
Institution:University College London NHS Foundation Trust, London, UK. Kavita.raj@nhs.net.; CHU de Lille, Univ Lille, INSERM U1286, Infinite, 59000, Lille, France.
Journal:Blood Cancer J. 2022 Sep 28;12(9):140. doi: 10.1038/s41408-022-00729-y.

9:Clinical view versus guideline adherence in ferritin monitoring and initiating iron chelation therapy in patients with myelodysplastic syndromes.
Authors:Rozema J, van Asten I, Kwant B, Kibbelaar RE, Veeger NJGM, de Wit H, van Roon EN, Hoogendoorn M
Institution:Unit of Pharmacotherapy, Epidemiology and Economics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands.; Department of Internal Medicine, Medical Centre Leeuwarden, Leeuwarden, The Netherlands.
Journal:Eur J Haematol. 2022 Dec;109(6):772-778. doi: 10.1111/ejh.13865. Epub 2022 Oct 2.

10:Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
Authors:Sekeres MA, Taylor J
Institution:Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
Journal:JAMA. 2022 Sep 6;328(9):872-880. doi: 10.1001/jama.2022.14578.

11:Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease.
Authors:Mohty R, Al Hamed R, Bazarbachi A, Brissot E, Nagler A, Zeidan A, Mohty M
Institution:Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA.; Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, Sorbonne University, and INSERM, Saint-Antoine Research Centre, 75012, Paris, France. mohamad.mohty@inserm.fr.
Journal:J Hematol Oncol. 2022 Aug 31;15(1):124. doi: 10.1186/s13045-022-01346-9.

12:SOHO State of the Art and Next Questions: Treatment of Higher-Risk Myelodysplastic Syndromes.
Authors:Aubrey BJ, Brunner AM
Institution:Harvard Medical School, Massachusetts General Hospital, Boston, MA. Electronic address: abrunner@mgh.harvard.edu.
Journal:Clin Lymphoma Myeloma Leuk. 2022 Dec;22(12):869-877. doi: 10.1016/j.clml.2022.07.012. Epub 2022 Jul 23.

13:Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study.
Authors:Platzbecker U, Götze KS, Kiewe P, Germing U, Mayer K, Radsak M, Wolff T, Chromik J, Sockel K, Oelschlägel U, Haase D, Illmer T, Al-Ali HK, Silling G, Reynolds JG, Zhang X, Attie KM, Shetty JK, Giagounidis A
Institution:Department of Hematology, Cellular Therapy and Hemostaseology, Leipzig University Hospital, Leipzig, Germany.; Marien Hospital Dusseldorf, Dusseldorf, Germany.
Journal:J Clin Oncol. 2022 Nov 20;40(33):3800-3807. doi: 10.1200/JCO.21.02476. Epub 2022 Aug 23.

14:Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents.
Authors:Lee S, Mohan S, Knupp J, Chamoun K, de Jonge A, Yang F, Baloglu E, Shah J, Kauffman MG, Shacham S, Bhatnagar B
Institution:Division of Hematology and Oncology, Weill Cornell Medicine, The New York Presbyterian Hospital, 520 East 70thStreet, Starr 341, New York, NY, 10021, USA. SLee259@its.jnj.com.; West Virginia University Cancer Institute, Wheeling Hospital, Wheeling, WV, USA.
Journal:J Hematol Oncol. 2022 Aug 3;15(1):103. doi: 10.1186/s13045-022-01319-y.

15:Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
Authors:Janssen JJWM, Löwenberg B, Manz M, Biemond BJ, Westerweel PE, Klein SK, Fehr M, Sinnige HAM, Efthymiou A, Legdeur MCJC, Pabst T, Gregor M, van der Poel MWM, Deeren D, Tick LW, Jongen-Lavrencic M, van Obbergh F, Boersma RS, de Weerdt O, Chalandon Y, Heim D, Spertini O, van Sluis G, Graux C, Stüssi G, van Norden Y, Ossenkoppele GJ
Institution:Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, loc. VUmc, Amsterdam, The Netherlands. j.janssen@amsterdamumc.nl.
Journal:Leukemia. 2022 Sep;36(9):2189-2195. doi: 10.1038/s41375-022-01657-3. Epub 2022 Jul 22.

16:Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia.
Authors:Woll PS, Yoshizato T, Hellström-Lindberg E, Fioretos T, Ebert BL, Jacobsen SEW
Institution:Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden.
Journal:J Intern Med. 2022 Aug;292(2):262-277. doi: 10.1111/joim.13535. Epub 2022 Jul 13.

17:Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Authors:Mishra A, Tamari R, DeZern AE, Byrne MT, Gooptu M, Chen YB, Deeg HJ, Sallman D, Gallacher P, Wennborg A, Hickman DK, Attar EC, Fernandez HF
Institution:Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.; Moffitt Cancer Center, Pembroke Pines, FL.
Journal:J Clin Oncol. 2022 Dec 1;40(34):3985-3993. doi: 10.1200/JCO.22.00181. Epub 2022 Jul 11.

18:G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial.
Authors:Stopka T, Minařík L, Dusilková N, Pešta M, Kulvait V, Špaček M, Zemanová Z, Kalousová M, Jonášová A
Institution:Haematology Clinic, General Faculty Hospital, Prague, Czech Republic. tstopka@lf1.cuni.cz.; Haematology Clinic, General Faculty Hospital, Prague, Czech Republic. Anna.Jonasova@vfn.cz.
Journal:Blood Cancer J. 2022 Jul 7;12(7):105. doi: 10.1038/s41408-022-00698-2.

19:Patient Preferences for Benefits, Risks, and Administration Route of Hypomethylating Agents in Myelodysplastic Syndromes.
Authors:Zeidan AM, Tsai JH, Karimi M, Schmier J, Jayade S, Zormpas E, Hassan A, Ruiters D, Anthony C, Hill K, Wert T, Botteman M
Institution:Section of Hematology, Department of Medicine, Yale School of Medicine, and Yale Cancer Center, New Haven, CT. Electronic address: Amer.zeidan@yale.edu.; OPEN Health, Bethesda, MD.
Journal:Clin Lymphoma Myeloma Leuk. 2022 Sep;22(9):e853-e866. doi: 10.1016/j.clml.2022.04.023. Epub 2022 May 2.

20:Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy.
Authors:Tarlock K, Sulis ML, Chewning JH, Pollard JA, Cooper T, Gamis A, Shenoy S, Kutny M, Horan J, Meshinchi S, Boelens JJ, Bleakley M, Carpenter PA, Kolb EA
Institution:Seattle Children's Hospital, Division of Hematology/Oncology, and University of Washington Seattle, Washington; Fred Hutchinson Cancer Research Center, Clinical Research Division and University of Washington, Seattle, Washington. Electronic address: Katherine.tarlock@seattlechildrens.org.; Nemours Center for Cancer and Blood Disorders, Alfred I. DuPont Hospital for Children, Wilmington, Delaware.
Journal:Transplant Cell Ther. 2022 Sep;28(9):530-545. doi: 10.1016/j.jtct.2022.06.005. Epub 2022 Jun 16.

21:Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes.
Authors:Santini V, Giagounidis A, Pelligra CG, Franco-Villalobos C, Tang D, Morison J, Beach CL, Hu A, Platzbecker U, Fenaux P
Institution:MDS Unit, AOU Careggi, DMSC, University of Florence. Florence, Italy. Electronic address: valeria.santini@unifi.it.; Service d'Hematologie Seniors, Hopital Saint-Louis, Assistance Publique Hopitaux de Paris, Universite de Paris, France.
Journal:Clin Lymphoma Myeloma Leuk. 2022 Sep;22(9):e874-e883. doi: 10.1016/j.clml.2022.05.001. Epub 2022 May 21.

22:What constitutes meaningful improvement in myelodysplastic syndromes?
Authors:Chandhok NS, Sekeres MA
Institution:Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Journal:Leuk Lymphoma. 2022 Nov;63(11):2528-2535. doi: 10.1080/10428194.2022.2084732. Epub 2022 Jun 14.

23:Outcomes after venetoclax with hypomethylating agents in myelodysplastic syndromes: a systematic review and meta-analysis.
Authors:Khanam R, Shahzad M, Chaudhary SG, Ali F, Shah Z, Pachika PS, Ahmed Z, Chattaraj A, Masood A, Ahmed N, Bansal R, Balusu R, Shune L, Anwar F, Hematti P, McGuirk JP, Yacoub A, Mushtaq MU
Institution:Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
Journal:Leuk Lymphoma. 2022 Nov;63(11):2671-2678. doi: 10.1080/10428194.2022.2084730. Epub 2022 Jun 10.

24:Clinical risk factors for patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplantation.
Authors:Teshigawara-Tanabe H, Hagihara M, Aoki J, Koyama S, Takahashi H, Nakajima Y, Kunimoto H, Tachibana T, Miyazaki T, Matsumoto K, Tanaka M, Yamazaki E, Fujisawa S, Kanamori H, Taguri M, Nakajima H
Institution:Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Journal:Hematology. 2022 Dec;27(1):620-628. doi: 10.1080/16078454.2022.2052601.

25:Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial.
Authors:Beelen DW, Stelljes M, Reményi P, Wagner-Drouet EM, Dreger P, Bethge W, Ciceri F, Stölzel F, Junghanß C, Labussiere-Wallet H, Schaefer-Eckart K, Grigoleit GU, Scheid C, Patriarca F, Rambaldi A, Niederwieser D, Hilgendorf I, Russo D, Socié G, Holler E, Glass B, Casper J, Wulf G, Basara N, Bieniaszewska M, Stuhler G, Verbeek M, La Rocca U, Finke J, Benedetti F, Pichlmeier U, Klein A, Baumgart J, Markiewicz M
Institution:Department of Bone Marrow Transplantation, West German Cancer Center, University of Duisburg-Essen, Essen, Germany.; Department of Hematology and Bone Marrow Transplantation, A. Miel?cki Independent Public Clinical Hospital, Katowice, Poland.
Journal:Am J Hematol. 2022 Aug;97(8):1023-1034. doi: 10.1002/ajh.26620. Epub 2022 Jun 8.

26:Autoimmune disorders associated with myelodysplastic syndromes: clinical, prognostic and therapeutic implications.
Authors:Fozza C, Murtas A, Caocci G, La Nasa G
Institution:Department of Medical, Surgical and Experimental Sciences, University of Sassari, Viale San Pietro 12, 07100 Sassari, Italy.; Department of Medical Sciences, University of Cagliari, Cagliari, Italy.
Journal:Leuk Res. 2022 Jun;117:106856. doi: 10.1016/j.leukres.2022.106856. Epub 2022 May 2.

27:Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial.
Authors:Miyazaki Y, Kiguchi T, Sato S, Usuki K, Ishiyama K, Ito Y, Suzuki T, Taguchi J, Chiba S, Dobashi N, Tomita A, Harada H, Handa H, Horiike S, Maeda T, Matsuda M, Ichikawa M, Hata T, Honda S, Iyama S, Suzushima H, Moriuchi Y, Kurokawa T, Yokota K, Ohtake S, Yamauchi T, Matsumura I, Kiyoi H, Naoe T
Institution:Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan. y-miyaza@nagasaki-u.ac.jp.; Department of Hematology, Nagoya Medical Center, Nagoya, Japan.
Journal:Int J Hematol. 2022 Aug;116(2):228-238. doi: 10.1007/s12185-022-03347-3. Epub 2022 May 4.

28:A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.
Authors:Sekeres MA, Schuster M, Joris M, Krauter J, Maertens J, Breems D, Gyan E, Kovacsovics T, Verma A, Vyas P, Wang ES, Ching K, O'Brien T, Gallo Stampino C, Ma WW, Kudla A, Chan G, Zeidan AM
Institution:Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, 1475 NW 12th Ave, Miami, FL, 33136, USA. msekeres@med.miami.edu.; Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA.
Journal:Ann Hematol. 2022 Aug;101(8):1689-1701. doi: 10.1007/s00277-022-04853-4. Epub 2022 Apr 30.

29:FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes.
Authors:Kim N, Norsworthy KJ, Subramaniam S, Chen H, Manning ML, Kitabi E, Earp J, Ehrlich LA, Okusanya OO, Vallejo J, Gehrke BJ, de Claro RA, Pazdur R
Institution:Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.
Journal:Clin Cancer Res. 2022 Aug 15;28(16):3411-3416. doi: 10.1158/1078-0432.CCR-21-4498.

30:Current Status of CPX-351 Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Authors:Alotaibi S, Niederwieser D, Ahmed SO, Sanz J, Mohty M, Aljurf M
Institution:Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, KSA. Electronic address: ShAlOtaibi@kfshrc.edu.sa.
Journal:Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):575-580. doi: 10.1016/j.clml.2022.02.008. Epub 2022 Feb 26.

31:Incidence and survival estimates for patients with myelodysplastic syndrome in the early 21st century: no evidence of improvement over time.
Authors:Pulte D, Jansen L, Brenner H
Institution:Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DFKZ), Heidelberg, Germany.
Journal:Leuk Lymphoma. 2022 Aug;63(8):1964-1969. doi: 10.1080/10428194.2022.2053529. Epub 2022 Mar 27.

32:New Approaches to Myelodysplastic Syndrome Treatment.
Authors:Bazinet A, Bravo GM
Institution:Department of Leukemia, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Box 428, Houston, TX, 77030, USA. gmontalban1@mdanderson.org.
Journal:Curr Treat Options Oncol. 2022 May;23(5):668-687. doi: 10.1007/s11864-022-00965-1. Epub 2022 Mar 23.

33:Outcome of therapy-related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A propensity score matched analysis.
Authors:Itonaga H, Kida M, Hamamura A, Uchida N, Ozawa Y, Fukuda T, Ueda Y, Kataoka K, Katayama Y, Ota S, Matsuoka KI, Kondo T, Eto T, Kanda J, Ichinohe T, Atsuta Y, Miyazaki Y, Ishiyama K
Institution:Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan.; Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan.
Journal:Hematol Oncol. 2022 Oct;40(4):752-762. doi: 10.1002/hon.2991. Epub 2022 Apr 5.

34:Myeloablative Versus Reduced-Intensity Conditioning With Fludarabine/Busulfan for Myelodysplastic Syndrome: A Propensity Score-Matched Analysis.
Authors:Kurosawa S, Shimomura Y, Itonaga H, Najima Y, Kobayashi T, Ozawa Y, Kanda Y, Kako S, Kawakita T, Matsuoka KI, Maruyama Y, Ota S, Nakazawa H, Imada K, Kimura T, Kanda J, Fukuda T, Atsuta Y, Ishiyama K
Institution:Division of Stem Cell and Molecular Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. Electronic address: shuhei-kurosawa@g.ecc.u-tokyo.ac.jp.; Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan.
Journal:Transplant Cell Ther. 2022 Jun;28(6):323.e1-323.e9. doi: 10.1016/j.jtct.2022.03.011. Epub 2022 Mar 13.

35:The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes.
Authors:Brailovski E, Li Q, Liu N, Leber B, Khalaf D, Sabloff M, Christou G, Yee K, Chodirker L, Parmentier A, Siddiqui M, Mamedov A, Zhang L, Liu Y, Earle CC, Cheung MC, Mittmann N, Buckstein RJ, Mozessohn L
Institution:Department of Medicine, University of Toronto, Toronto, ON, Canada. eugene.brailovski@mail.utoronto.ca.
Journal:Ann Hematol. 2022 May;101(5):1023-1030. doi: 10.1007/s00277-022-04802-1. Epub 2022 Feb 22.

36:The impact of race and ethnicity on outcomes of patients with myelodysplastic syndromes: a population-based analysis.
Authors:Goksu SY, Ozer M, Goksu BB, Wang R, Khatib J, Patel PA, Vusirikala M, Cole S, Seyhanli A, Collins RH, Chung S, Zeidan AM, Madanat YF
Institution:Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
Journal:Leuk Lymphoma. 2022 Jul;63(7):1651-1659. doi: 10.1080/10428194.2022.2032034. Epub 2022 Feb 8.

37:Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS).
Authors:Chan O, Ali NA, Sallman D, Padron E, Lancet J, Komrokji R
Institution:Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL. Electronic address: Rami.Komrokji@moffitt.org.
Journal:Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):e467-e476. doi: 10.1016/j.clml.2022.01.002. Epub 2022 Jan 10.

38:Excellent Prognosis of Low-Risk Myelodysplastic Syndromes (MDS) Without Detectable Myeloid-Related Mutations.
Authors:Polprasert C, Niparuck P, Rattanathammethee T, Chuncharunee S, Kobbuaklee S, Songserm K, Suksusut A, Trithiphen S, Lanamtieng T, Kongkiatkamon S, Chanswangphuwana C, Lawasut P, Bunworasate U, Rojnuckarin P
Institution:Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Research Unit in Translational Hematology, Chulalongkorn University, Bangkok, Thailand. Electronic address: rojnuckarinp@gmail.com.
Journal:Clin Lymphoma Myeloma Leuk. 2022 May;22(5):e293-e299. doi: 10.1016/j.clml.2021.10.015. Epub 2021 Nov 2.

39:Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms.
Authors:O'Hagan Henderson S, Frietsch JJ, Hilgendorf I, Hochhaus A, Köhne CH, Casper J
Institution:Onkologie und Hamatologie, Universitatsklinikum Oldenburg, Klinik Fur Innere Medizin II, Oldenburg, Germany.
Journal:J Cancer Res Clin Oncol. 2022 Oct;148(10):2599-2609. doi: 10.1007/s00432-021-03836-8. Epub 2021 Oct 21.

For a FREE PREVIEW of the Medifocus Guidebook on Myelodysplastic Syndromes click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Myelodysplastic Syndromes click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Myelodysplastic Syndromes...
at a Special 20% Discount


Medifocus Guidebook on Myelodysplastic Syndromes

Updated: January 18, 2023
179 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Myelodysplastic Syndromes is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $37.45
  • Less 20% Discount = - $7.10
  • Discounted Price = $30.35(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $31.20
  • Less 20% Discount = - $6.45
  • Discounted Price = $24.75

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

MS340997392

Coupon Expires: March 3, 2023



What Our Customers Are Saying...

"I purchased the MediFocus Guidebook on Myelodysplastic Syndromes to help my father understand the disease that he has. Doctors in France do not communicate very well the various treatment options neither do they tell you about the prognosis with enough clarity and confidence. We live in France and we believe there is no equivalent in Europe to the service you offer. We have read the Guidebook attentively and have learned a great deal about this condition. The wording is simple enough to be understandable even for non-native English speakers. It was money well spent!"
P.M.
Saint Ismier, France


"Your MediFocus Guidebook on Myelodysplastic Syndromes has been a valuable companion in providing wise counsel to a beleaguered soul. Many times I was comforted by knowing that I could have my questions answered correctly and completely by using your Guidebook. I wouldn't be without it for anything. Thank you again and again."
S.M.
Rockville, Maryland


"Your Medifocus Guidebook on Myelodysplastic Syndromes has been extremely valuable to me in understanding the complicated disease that afflicts me. It can be very depressing but to understand it intellectually can be very calming and heartening. Fear of the unknown is most devastating and your Guidebook provides the facts in an understandable way without 'watering-down' the science. Thank you for your outstanding publication."
N.M.
Los Angeles, California



  
Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2023 Medifocus, Inc. All rights reserved.